Skolarus Ted A, Dunn Rodney L, Sanda Martin G, Chang Peter, Greenfield Thomas K, Litwin Mark S, Wei John T
Department of Urology, Dow Division of Health Services Research, University of Michigan, Ann Arbor, MI; Division of Oncology, University of Michigan, Ann Arbor, MI; VA HSR&D Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, MI.
Department of Urology, Dow Division of Health Services Research, University of Michigan, Ann Arbor, MI.
Urology. 2015 Jan;85(1):101-5. doi: 10.1016/j.urology.2014.08.044.
To establish a score threshold that constitutes a clinically relevant change for each domain of the Expanded Prostate Cancer Index Composite (EPIC) Short Form (EPIC-26). Although its use in clinical practice and clinical trials has increased worldwide, the clinical interpretation of this 26-item disease-specific patient-reported quality of life questionnaire for men with localized prostate cancer would be facilitated by characterization of score thresholds for clinically relevant change (the minimally important differences [MIDs]).
We used distribution- and anchor-based approaches to establish the MID range for each EPIC-26 domain (urinary, sexual, bowel, and vitality/hormonal) based on a prospective multi-institutional cohort of 1201 men treated for prostate cancer between 2003 and 2006 and followed up for 3 years after treatment. For the anchor-based approach, we compared within-subject and between-subject score changes for each domain to an external "anchor" measure of overall cancer treatment satisfaction.
We found the bowel and vitality/hormonal domains to have the lowest MID range (a 4-6 point change should be considered clinically relevant), whereas the sexual domain had the greatest MID values (10-12). Urinary incontinence appeared to have a greater MID range (6-9) than the urinary irritation/obstruction domain (5-7).
Using 2 independent approaches, we established the MIDs for each EPIC-26 domain. A definition of these MID values is essential for the researcher or clinician to understand when changes in symptom burden among prostate cancer survivors are clinically relevant.
为扩展前列腺癌指数综合量表简表(EPIC-26)的每个领域确定构成临床相关变化的评分阈值。尽管其在全球临床实践和临床试验中的应用有所增加,但对于局限性前列腺癌男性患者的这份包含26个项目的疾病特异性患者报告生活质量问卷,若能确定临床相关变化(最小重要差异[MIDs])的评分阈值,将有助于其临床解读。
我们采用基于分布和锚定的方法,基于2003年至2006年间接受前列腺癌治疗并在治疗后随访3年的1201名男性的前瞻性多机构队列,为EPIC-26的每个领域(泌尿、性、肠道和活力/激素)确定MID范围。对于基于锚定的方法,我们将每个领域的受试者内和受试者间评分变化与总体癌症治疗满意度的外部“锚定”指标进行比较。
我们发现肠道和活力/激素领域的MID范围最低(4至6分的变化应被视为临床相关),而性领域的MID值最大(10至12)。尿失禁的MID范围似乎比尿路刺激/梗阻领域(5至7)更大(6至9)。
我们使用两种独立的方法确定了EPIC-26每个领域的MIDs。这些MID值的定义对于研究人员或临床医生理解前列腺癌幸存者症状负担的变化何时具有临床相关性至关重要。